Drug Profile
Vasostatin
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 17 Feb 2006 Vasostatin is available for licensing (http://ott.od.nih.gov)
- 16 Dec 2003 Preclinical trials in Cancer in USA (Intratumoural)